Department of Physiological Sciences, State University of Londrina, Londrina, PR, 86051-990, Brazil.
Department of Physiological Sciences, State University of Maringá, Maringá, PR, 87020-900, Brazil.
Pharmacol Rep. 2023 Dec;75(6):1571-1587. doi: 10.1007/s43440-023-00533-w. Epub 2023 Oct 7.
Insulin (INS) resistance and hypoinsulinemia commonly observed in cancer-carrying, can contribute to cachexia. However, the effects of INS and INS sensitizers, such as pioglitazone (PIO), particularly when used in combination therapy, on cancer cachexia have not been evaluated sufficiently. We investigated the effects of INS and PIO, at various doses, either isolated or combined, on cachexia in Walker-256 tumor-bearing rats (TB rats).
INS or INS + PIO were administered in TB rats, for 6 or 12 days, starting from the day of tumor cells inoculation.
INS at 18 or 27 U/kg (12-days treatment), but not 9 U/kg, reduced fat loss and slightly prevented weight loss. However, INS 18 U/kg + PIO 5, 10, 20, or 40 mg/kg (6 or 12-day treatment) reduced fat loss and markedly prevented weight loss but did not affect muscle wasting. While TB rats lost weight (37.9% in 12 days), TB rats treated with INS 18 U/kg + PIO 5 mg/kg showed pronounced weight gain (73.7%), which was greater than the sum (synergism) of the weight gains promoted by isolated treatments with INS 18 U/kg (14.7%) or PIO 5 mg/kg (13.1%). The beneficial effect of the INS 18 U/kg + PIO 5 mg/kg on weight loss was associated with improved INS sensitivity, as indicated by the higher blood glucose clearance constant (kITT), decreased levels of free fatty acids and triacylglycerols (INS resistance-inducing factors) in the blood, and increased expression of p-Akt (INS signaling pathway protein) in adipose tissue.
The combined treatment with INS 18 U/kg + PIO 5 mg/kg was more effective in preventing advanced cachexia in TB rats than each treatment alone, emerging as the best approach, considering the lower dosage and higher efficacy. This combination completely preserved adipose mass and markedly reduced weight loss through a synergistic mechanism linked to improved insulin sensitivity. These findings provide new insights into the importance of drug combinations in effectively combating fat loss in advanced cachexia.
癌症患者常伴有胰岛素(INS)抵抗和低胰岛素血症,这可能导致恶病质。然而,尚未充分评估 INS 和 INS 敏化剂(如吡格列酮(PIO)),特别是在联合治疗时,对癌症恶病质的影响。我们研究了不同剂量的 INS 和 PIO 单独或联合使用对 Walker-256 肿瘤荷瘤大鼠(TB 大鼠)恶病质的影响。
从肿瘤细胞接种之日起,在 TB 大鼠中连续 6 或 12 天给予 INS 或 INS+PIO。
INS 18 或 27 U/kg(12 天治疗),但不是 9 U/kg,可减少脂肪丢失并轻微预防体重减轻。然而,INS 18 U/kg+PIO 5、10、20 或 40 mg/kg(6 或 12 天治疗)减少脂肪丢失并显著预防体重减轻,但不影响肌肉消耗。虽然 TB 大鼠体重减轻(12 天内减轻 37.9%),但用 INS 18 U/kg+PIO 5 mg/kg 治疗的 TB 大鼠体重明显增加(增加 73.7%),大于 INS 18 U/kg(14.7%)或 PIO 5 mg/kg(13.1%)单独治疗促进的体重增加之和(协同作用)。INS 18 U/kg+PIO 5 mg/kg 对体重减轻的有益作用与 INS 敏感性的提高有关,表现为血糖清除常数(kITT)更高,血液中游离脂肪酸和三酰甘油(诱导 INS 抵抗的因素)水平降低,以及脂肪组织中 p-Akt(INS 信号通路蛋白)的表达增加。
与单独治疗相比,INS 18 U/kg+PIO 5 mg/kg 联合治疗更能有效预防 TB 大鼠晚期恶病质,考虑到较低的剂量和更高的疗效,这是最佳方法。这种组合通过一种协同机制完全保留了脂肪质量,并显著减少了体重减轻,这种协同机制与提高胰岛素敏感性有关。这些发现为药物联合在有效对抗晚期恶病质中脂肪丢失方面的重要性提供了新的见解。